ADAR1 Capital Management, LLC 13F Holdings · Q2 2026
ADAR1 Capital Management, LLC reported 263 securities worth $2.19B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: ABVX (11.28%), PTGX (5.39%), SPY (5.27%). Among its top 25 positions this quarter: 1 new, 13 added, 10 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ABVX | ABIVAX SA | $246.4M | 11.28% | 1.8M | Added |
| 2 | PTGX | PROTAGONIST THERAPEUTICS INC | $117.8M | 5.39% | 960,863 | Trimmed |
| 3 | SPY | STATE STR SPDR S&P 500 ETF T | $115.1M | 5.27% | 154,087 | Added |
| 4 | ROIV | ROIVANT SCIENCES LTD | $111.7M | 5.11% | 3.2M | Trimmed |
| 5 | IMVT | IMMUNOVANT INC | $89.8M | 4.11% | 2.3M | Trimmed |
| 6 | ZLAB | ZAI LAB LTD | $64.0M | 2.93% | 3.4M | Added |
| 7 | AGIO | AGIOS PHARMACEUTICALS INC | $47.8M | 2.19% | 1.3M | Added |
| 8 | CRNX | CRINETICS PHARMACEUTICALS IN | $45.7M | 2.09% | 1.2M | Added |
| 9 | BOXX | EA SERIES TRUST | $39.5M | 1.81% | 337,125 | Hold |
| 10 | CYTK | CYTOKINETICS INC | $39.0M | 1.79% | 457,907 | Trimmed |
| 11 | SEPN | SEPTERNA INC | $31.5M | 1.44% | 940,747 | Trimmed |
| 12 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $31.0M | 1.42% | 3.1M | Trimmed |
| 13 | EDIT | EDITAS MEDICINE INC | $28.8M | 1.32% | 8.9M | New |
| 14 | DNLI | DENALI THERAPEUTICS INC | $26.5M | 1.21% | 1.0M | Trimmed |
| 15 | SYRE | SPYRE THERAPEUTICS INC | $25.2M | 1.15% | 283,982 | Trimmed |
| 16 | VIR | VIR BIOTECHNOLOGY INC | $25.0M | 1.15% | 2.5M | Trimmed |
| 17 | PRAX | PRAXIS PRECISION MEDICINES I | $24.9M | 1.14% | 74,253 | Added |
| 18 | INSM | INSMED INC | $24.4M | 1.12% | 228,520 | Added |
| 19 | CLDX | CELLDEX THERAPEUTICS INC NEW | $23.1M | 1.05% | 619,542 | Added |
| 20 | VKTX | VIKING THERAPEUTICS INC | $22.4M | 1.02% | 574,038 | Added |
| 21 | TSHA | TAYSHA GENE THERAPIES INC | $20.7M | 0.95% | 3.0M | Added |
| 22 | MNPR | MONOPAR THERAPEUTICS INC | $20.1M | 0.92% | 217,595 | Trimmed |
| 23 | OVID | OVID THERAPEUTICS INC | $20.0M | 0.91% | 7.4M | Added |
| 24 | ELVN | ENLIVEN THERAPEUTICS INC | $19.7M | 0.90% | 387,718 | Added |
| 25 | ENTA | ENANTA PHARMACEUTICALS INC | $19.6M | 0.90% | 1.3M | Added |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR